Xeris Biopharma Holdings

NasdaqGS:XERS Stock Report

Mkt Cap: US$179.5m

We’ve recently updated our valuation analysis.

Xeris Biopharma Holdings Valuation

Is XERS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for XERS?

Other financial metrics that can be useful for relative valuation.

XERS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.3x
Enterprise Value/EBITDA-2.6x
PEG Ration/a

Price to Sales Ratio vs Peers

How does XERS's PS Ratio compare to its peers?

The above table shows the PS ratio for XERS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average4.5x
PRPH ProPhase Labs
1.1x-30.1%US$167.3m
MRNS Marinus Pharmaceuticals
10.9x63.0%US$215.2m
OCUL Ocular Therapeutix
4.7x36.4%US$231.8m
JUSH.F Jushi Holdings
1.4x39.0%US$371.6m
XERS Xeris Biopharma Holdings
1.8x26.6%US$179.5m

Price-To-Sales vs Peers: XERS is good value based on its Price-To-Sales Ratio (1.8x) compared to the peer average (4.5x).


Price to Earnings Ratio vs Industry

How does XERS's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a10.7%
n/an/an/a

Price-To-Sales vs Industry: XERS is good value based on its Price-To-Sales Ratio (1.8x) compared to the US Pharmaceuticals industry average (2.9x)


Price to Sales Ratio vs Fair Ratio

What is XERS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

XERS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.8x
Fair PS Ratio4.6x

Price-To-Sales vs Fair Ratio: XERS is good value based on its Price-To-Sales Ratio (1.8x) compared to the estimated Fair Price-To-Sales Ratio (4.6x).


Share Price vs Fair Value

What is the Fair Price of XERS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: XERS ($1.32) is trading below our estimate of fair value ($17.28)

Significantly Below Fair Value: XERS is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst XERS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$1.32
US$5.25
+297.7%
15.8%US$6.00US$4.00n/a4
Nov ’23US$1.59
US$5.50
+245.9%
15.7%US$6.00US$4.00n/a4
Oct ’23US$1.56
US$6.00
+284.6%
0%US$6.00US$6.00n/a3
Sep ’23US$1.72
US$6.00
+248.8%
0%US$6.00US$6.00n/a3
Aug ’23US$1.51
US$6.00
+297.4%
0%US$6.00US$6.00n/a3
Jul ’23US$1.50
US$6.10
+306.7%
3.3%US$6.50US$6.00n/a5
Jun ’23US$2.17
US$6.25
+188.0%
6.1%US$7.00US$6.00n/a6
May ’23US$2.44
US$6.25
+156.1%
6.1%US$7.00US$6.00n/a6
Apr ’23US$2.58
US$6.20
+140.3%
6.5%US$7.00US$6.00n/a5
Mar ’23US$2.38
US$6.60
+177.3%
12.1%US$8.00US$6.00n/a5
Feb ’23US$2.13
US$7.00
+228.6%
12.8%US$8.00US$6.00n/a5
Jan ’23US$2.93
US$6.88
+134.8%
15.2%US$8.00US$5.40n/a5
Dec ’22US$1.95
US$6.25
+220.5%
19.9%US$8.00US$4.25n/a5

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies